Cipla’s FDA-compliant facilities and its investments in US-based units place it in a strong position to weather potential ...

Shivam Puri, CEO, Cipla Health, discusses the brand proposition of Prolyte ORS, shares strategy that helped brand achieve Rs ...

On technical setup, the scrip traded higher than the 5-day, 10-, 150-day and 200-day simple moving averages (SMAs) but lower ...

The Biosecurity Act, which prohibits US pharma companies from doing business with certain countries that are considered adversaries, presents a unique opportunity for Indian pharma companies, Cipla ...

(Reuters) -Cipla, India's third-largest generic drugmaker by sales, reported a 15.2% rise in second-quarter profit that beat ...

Cipla's shares are in focus as the company reported a 15% YoY increase in consolidated net profit to Rs 1,303 crore for Q2 ...

Shares of pharmaceutical giant Cipla dipped 5 per cent at Rs 1,403 per share on the NSE in Wednesday's intraday deals: Cipla ...

Cipla Ltd, a major player in the Indian pharmaceutical sector, currently trades at ₹1,418. This price reflects a decrease of ...

Total research and development spend reached Rs 385 crore, equivalent to 5.5 per cent of sales, a 2 per cent increase Y-o-Y.

Cipla share price: Cipla Ltd shares fell the most in terms of percentage among all the 50 companies in the NSE Nifty today on ...

The Mumbai-based firm’s consolidated revenue from operations rose to ₹7,051.02 crore in the September quarter, up from ₹6,678 ...

Cipla reported a 13% year-on-year increase in Q2 FY25 profit, with consolidated revenue rising to Rs 7,051.02 crore.